Fig. 1
From: Plasma SuPAR and therapeutic response to erenumab in migraine: a REFORM study
Study flow. legend: Blood samples analyzed for plasma soluble urokinase-type plasminogen activator receptor (suPAR) were collected at baseline (Screening visit during weeks − 5 to -6), Week 24 (± 2), and Week 48 (± 4). Treatment with erenumab was administered every 28th day from day 1 (1st injection) to Week 24. Detailed reasons for exclusion are available in Supplementary Figure S1. Abbreviations: CGRP-mAbs, calcitonin gene-related peptide monoclonal antibodies; MMDs, monthly migraine days; suPAR, soluble urokinase-type plasminogen activator receptor